Last reviewed · How we verify

ANTARA® (fenofibrate) — Competitive Intelligence Brief

ANTARA® (fenofibrate) (ANTARA® (fenofibrate)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrate (PPARα agonist). Area: Cardiovascular.

marketed Fibrate (PPARα agonist) PPARα (Peroxisome proliferator-activated receptor alpha) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ANTARA® (fenofibrate) (ANTARA® (fenofibrate)) — Ranbaxy Laboratories Limited. Fenofibrate activates peroxisome proliferator-activated receptor alpha (PPARα) to reduce triglycerides and increase HDL cholesterol.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ANTARA® (fenofibrate) TARGET ANTARA® (fenofibrate) Ranbaxy Laboratories Limited marketed Fibrate (PPARα agonist) PPARα (Peroxisome proliferator-activated receptor alpha)
Comparator: fenofibrate monotherapy Comparator: fenofibrate monotherapy Organon and Co phase 3 Fibrate (PPARα agonist) PPARα (Peroxisome proliferator-activated receptor alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrate (PPARα agonist) class)

  1. Organon and Co · 1 drug in this class
  2. Ranbaxy Laboratories Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ANTARA® (fenofibrate) — Competitive Intelligence Brief. https://druglandscape.com/ci/antara-fenofibrate. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: